TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16151790

Group type: EXPERIMENTAL
Intervention: Partial liquid ventilation
Number of subjects: 0
Study: 12138347

Group type: EXPERIMENTAL
Intervention: Saquinavir soft-gel capsules 1200 mg three times daily + zidovudine + optional lamivudine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lamivudine (optional)
Number of subjects: 18
Study: 10320157

Group type: EXPERIMENTAL
Intervention: Hextend
Number of subjects: 120

Group type: COMPARATOR
Intervention: HES
Number of subjects: 120
Study: 8675575

Group type: EXPERIMENTAL
Intervention: LAD plus estrogen
Number of subjects: 19

Group type: COMPARATOR
Intervention: LAD plus placebo
Number of subjects: 19
Study: 1961669

Group type: EXPERIMENTAL
Intervention: Trained group (underwent a specifically designed program lasting six months)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Untrained group (no specific training program)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (8 boys of the same age)
Number of subjects: 26
Study: 6123070

Group type: EXPERIMENTAL
Intervention: lormetazepam 1 mg (Noctamid)
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study: 30858014

Group type: EXPERIMENTAL
Intervention: REACH cleaning bundle intervention
Number of subjects: 11
Study: 29524192

Group type: EXPERIMENTAL
Intervention: ChronoMag® (100 mg magnesium element)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Reference tablet (300 mg magnesium element)
Number of subjects: 12
Study: 26917334

Group type: EXPERIMENTAL
Intervention: Medical contact lenses (CLs)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Daily-wear CLs
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Medical CL fitting
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Scleral lenses and soft lenses
Number of subjects: 281
Study: 24184132

Group type: EXPERIMENTAL
Intervention: Daclatasvir (60 mg, once daily), Asunaprevir (200 mg, twice daily), BMS-791325 (75 or 150 mg, twice daily) for 12 or 24 weeks
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Daclatasvir, Asunaprevir, BMS-791325
Number of subjects: 66
Study: 22971490

Group type: EXPERIMENTAL
Intervention: Bilateral superficial cervical plexus block with 20 ml 0.5% ropivacaine
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo (20 ml saline)
Number of subjects: 135
Study: 20010459

Group type: EXPERIMENTAL
Intervention: CYP3A5*3/*3 genotype group
Number of subjects: 29

Group type: COMPARATOR
Intervention: CYP3A5*1/*1+*1/*3 genotype group
Number of subjects: 29
Study: 17610807

Group type: EXPERIMENTAL
Intervention: Direct individual therapy (SLT working individually with a child)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Indirect individual therapy (SLTA working individually with a child)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Direct group therapy (SLT working with a small group of children)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Indirect group therapy (SLTA working with a small group of children)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Community-based SLT services (Control)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Direct therapy from an SLT
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Indirect group therapy
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Direct individual therapy
Number of subjects: 161
Study: 15175847

Group type: EXPERIMENTAL
Intervention: Case-selection strategy with open access to DXA scans for 12 months
Number of subjects: 10

Group type: COMPARATOR
Intervention: No case-finding strategy and no DXA scan access
Number of subjects: 10
Study: 11915063

Group type: EXPERIMENTAL
Intervention: Local anesthetic (1% mepivacaine, 0.2% tetracaine, epinephrine 1:200,000) plus buprenorphine, 0.3 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Local anesthetic-only axillary block, and IM buprenorphine 0.3 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Local anesthetic-only axillary block and IM saline
Number of subjects: 60
Study: 9690311

Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with chemotherapy (exact regimen not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher radiation doses, conformal radiotherapy, altered fractionation schedules, and possibly adjuvant surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New combined modality strategies and new drugs
Number of subjects: 0
Study: 7621761

Group type: EXPERIMENTAL
Intervention: Manual vacuum aspiration (MVA)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Evacuation by curettage (E by C)
Number of subjects: 199
Study: 2361193

Group type: EXPERIMENTAL
Intervention: Pilocarpine gel
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: 1% Acetylcholine chloride
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: 0.01% Carbachol
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: 0.005% Carbachol
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: 0.01% Carbachol (full-strength)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: 0.005% Carbachol (half-strength)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 172
Study: 6751839

Group type: EXPERIMENTAL
Intervention: Inspiratory resistance training program
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study: 31100155

Group type: EXPERIMENTAL
Intervention: Local treatment using the sutured intravitreal fluocinolone acetonide implant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Systemic treatment consisting of oral steroids and conventional steroid‐sparing immunosuppression
Number of subjects: 0
Study: 28371205

Group type: EXPERIMENTAL
Intervention: Tofogliflozin 20 mg once/day
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study: 25977128

Group type: EXPERIMENTAL
Intervention: EHR checklist users
Number of subjects: 60
Study: 23357717

Group type: EXPERIMENTAL
Intervention: Baseline energy loss index (ELI)
Number of subjects: 1563
Study: 21344271

Group type: EXPERIMENTAL
Intervention: Endurance training (6-week laboratory-based program)
Number of subjects: 58
Study: 19057513

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Bisoprolol 5 mg
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCT) 25 mg
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study: 20535927

Group type: EXPERIMENTAL
Intervention: Shenqi Fuzheng Injection (SFI) combined with chemotherapy (FOLFOX protocol)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Chemotherapy (FOLFOX protocol) alone
Number of subjects: 40
Study: 15574127

Group type: EXPERIMENTAL
Intervention: 10 mg of ramipril alone
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 50 mg of sildenafil alone
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Combination of ramipril and sildenafil
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 12169969

Group type: EXPERIMENTAL
Intervention: Heidelberg Retina Tomograph II stereometric parameters
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Moorfields regression analysis
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Progression analysis software
Number of subjects: 50
Study: 15539283

Group type: EXPERIMENTAL
Intervention: Fish oil concentrate (FOC) 1 g/14 kg body weight/day for 4 weeks
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 6
Study: 7786833

Group type: EXPERIMENTAL
Intervention: celiprolol 200 mg daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: metoprolol 100 mg daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: celiprolol
Number of subjects: 40

Group type: COMPARATOR
Intervention: metoprolol
Number of subjects: 40
Study: 2361721

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Analgin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study: 154372

Group type: EXPERIMENTAL
Intervention: Cholebrin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Telepaque
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cholebrin and Telepaque
Number of subjects: 100
Study: 12086366

Group type: EXPERIMENTAL
Intervention: BCG vaccination (58.2 x 10(7) CFUs)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 30047538

Group type: EXPERIMENTAL
Intervention: Trimetazidine
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no trimetazidine)
Number of subjects: 200
Study: 27442052

Group type: EXPERIMENTAL
Intervention: Prewarming (forced-air warming during induction of anesthesia)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no prewarming)
Number of subjects: 40
Study: 24332141

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 4323

Group type: COMPARATOR
Intervention: Eptifibatide
Number of subjects: 4323
Study: 22150065

Group type: EXPERIMENTAL
Intervention: 1.5 W/100 Hz
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 3.0 W/100 Hz
Number of subjects: 72

Group type: COMPARATOR
Intervention: No irradiation (control)
Number of subjects: 72
Study: 20938912

Group type: EXPERIMENTAL
Intervention: Narlaprevir (800 mg three times daily without ritonavir)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Narlaprevir (400 mg twice daily with 200 mg ritonavir twice daily)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Narlaprevir (with or without ritonavir) in combination with PEG‐IFN‐α‐2b
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard of care (PEG‐IFN‐α‐2b and ribavirin treatment)
Number of subjects: 40
Study: 18574771

Group type: EXPERIMENTAL
Intervention: Granulocyte-colony-stimulating factor (G-CSF) mobilization, PBMC collection by leukapheresis and PBMC transplant therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Granulocyte-colony-stimulating factor (G-CSF) mobilization for 4 days
Number of subjects: 40
Study: 16105609

Group type: EXPERIMENTAL
Intervention: Brimonidine
Number of subjects: 19

Group type: COMPARATOR
Intervention: Dapiprazole
Number of subjects: 19
Study: 12046816

Group type: EXPERIMENTAL
Intervention: Topical calcipotriol monotherapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Untreated control lesions
Number of subjects: 24
Study: 10412920

Group type: EXPERIMENTAL
Intervention: CoQ10 treatment (intravenous and intracoronary)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no CoQ10 treatment)
Number of subjects: 24
Study: 8585104

Group type: EXPERIMENTAL
Intervention: Intravenous administration of 25 mg sematilide HCl
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral administration of 25 mg sematilide HCl
Number of subjects: 0
Study: 2180144

Group type: EXPERIMENTAL
Intervention: Carbonyl iron (100 mg orally at bedtime for 56 days)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Carbonyl iron
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Routine screening
Number of subjects: 99
Study: 91432

Group type: EXPERIMENTAL
Intervention: Surgicopathologic staging system based on serum alphafetoprotein and human chorionic gonadotropin determination before and/or after orchiectomy and lymphadenectomy.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional staging system using lymphangiogram, iv pyelogram, and inferior venacavogram.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy with or without cytoreductive surgery.
Number of subjects: 0
Study: 31530556

Group type: EXPERIMENTAL
Intervention: Zostavax (live-attenuated herpes zoster vaccine)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 29644582

Group type: EXPERIMENTAL
Intervention: Riluzole 200 mg per day for 5 weeks
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo for 5 weeks
Number of subjects: 8
Study: 26997495

Group type: EXPERIMENTAL
Intervention: Fagerström Test of Cigarette Dependence (FTCD) score
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Expired carbon monoxide (CO) level
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Number of cigarettes smoked per day
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Frequency of urges to smoke
Number of subjects: 784
Study: 25128327

Group type: EXPERIMENTAL
Intervention: Sedentary-ESA (SE)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Training-placebo (TP)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Training-ESA (TE)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sedentary-placebo (SP)
Number of subjects: 36
Study: 22772319

Group type: EXPERIMENTAL
Intervention: Etanercept (50 mg/week)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sulfasalazine (≤ 3 g/day)
Number of subjects: 0
Study: 20134284

Group type: EXPERIMENTAL
Intervention: Motivational message pamphlet emphasizing learning CPR and AED use to save someone they love and the 3-minute window for response time
Number of subjects: 220

Group type: COMPARATOR
Intervention: Identical pamphlet without the 2 motivational statements (comparison group)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Both groups (treatment and control)
Number of subjects: 220
Study: 17289895

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with cisplatin and vinorelbine
Number of subjects: 265

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 265
Study: 16128935

Group type: EXPERIMENTAL
Intervention: Omeprazole (group A - 15 patients)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (group B - 15 patients)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Patients with documented GERD
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 44
Study: 11471577

Group type: EXPERIMENTAL
Intervention: Acupuncture to the most affected knee only (Group A)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Acupuncture to both knees (Group B)
Number of subjects: 44
Study: 9492129

Group type: EXPERIMENTAL
Intervention: Lidocaine, epinephrine, and tetracaine (LET) solution
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (sterile water) solution
Number of subjects: 60
Study: 8060627

Group type: EXPERIMENTAL
Intervention: Transarterial brachial plexus block with 60 to 70 ml of local anesthetic solution
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Experience in performing the block
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Transarterial brachial plexus block
Number of subjects: 346
Study: 2493800

Group type: EXPERIMENTAL
Intervention: Oral doxapram (300 mg and 600 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine (0.12 mg kg‐1 i.m.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Doxapram alone (300 mg and 600 mg)
Number of subjects: 0
Study: 30653519

Group type: EXPERIMENTAL
Intervention: Screening questionnaire for epilepsy
Number of subjects: 4768

Group type: EXPERIMENTAL
Intervention: Screening questionnaire for WSCH
Number of subjects: 4768

Group type: EXPERIMENTAL
Intervention: Adjusted prevalence estimates for epilepsy and WSCH
Number of subjects: 4768
Study: 28078435

Group type: EXPERIMENTAL
Intervention: Supervised exercise program
Number of subjects: 78

Group type: COMPARATOR
Intervention: Home-based exercise program
Number of subjects: 78
Study: 25960104

Group type: EXPERIMENTAL
Intervention: Experimental gingivitis group (n = 40) stopped brushing and flossing, used only fluoride anti‐cavity mouth rinse for 21 days.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (n = 40) conducted an oral hygiene regimen: brushing twice daily with sodium fluoride dentifrice, flossing twice daily, and mouth rinsing with anti‐cavity fluoride rinse once daily.
Number of subjects: 80
Study: 23046948

Group type: COMPARATOR
Intervention: Cocoa-nut cream (CC)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cocoa polyphenol extract in free form (FPC)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cocoa polyphenol extract encapsulated (EPC)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: EPC
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: FPC
Number of subjects: 12

Group type: COMPARATOR
Intervention: CC
Number of subjects: 12
Study: 21549529

Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 30
Study: 19346370

Group type: EXPERIMENTAL
Intervention: 100 mg pafuramidine eight days before challenge
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 100 mg pafuramidine the day before challenge
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 17119522

Group type: EXPERIMENTAL
Intervention: ExCLA (exercise + CLA)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: CLA (CLA supplementation only)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Ex (exercise only)
Number of subjects: 44

Group type: COMPARATOR
Intervention: C (control group)
Number of subjects: 44
Study: 15123336

Group type: EXPERIMENTAL
Intervention: Emulsified medium chain triglycerides (MCTs)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 12463030

Group type: EXPERIMENTAL
Intervention: Chloroquine (25 mg base/kg over 3 days)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Sulfadoxine‐pyrimethamine
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Chloroquine (in vitro)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Mefloquine (in vitro)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Quinine (in vitro)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Amodiaquine (in vitro)
Number of subjects: 66
Study: 9022434

Group type: EXPERIMENTAL
Intervention: Practice doctors
Number of subjects: 2152

Group type: COMPARATOR
Intervention: Deputising doctors
Number of subjects: 2152
Study: 8160983

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 75

Group type: COMPARATOR
Intervention: Sufentanil increments
Number of subjects: 75
Study: 3128465

Group type: EXPERIMENTAL
Intervention: Nitroglycerin infusion (200 micrograms/min)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Vasopressin (0.4 IU/min)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination of vasopressin and nitroglycerin
Number of subjects: 12
Study: 31581929

Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (200 mmHg pressure, twice daily for 10-14 days)
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Guideline-based therapy (control group)
Number of subjects: 1800
Study: 30303980

Group type: EXPERIMENTAL
Intervention: Augmented 40mcg HBV dose schedule
Number of subjects: 0

Group type: COMPARATOR
Intervention: Seasonal influenza vaccination (Fluvax)
Number of subjects: 0
Study: 26545149

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (group D, N=25) at 0.5 µg/kg over 10 minutes, followed by an infusion at 0.5 µg/kg/h until the end of surgery
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal saline (group S, N=25)
Number of subjects: 50
Study: 26253520

Group type: EXPERIMENTAL
Intervention: Progressive resistance training (PRT) with 220 g of lean red meat (raw weight) divided into two 80 g servings on training days
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control PRT with ≥1 serving (1/2 cup) of rice and/or pasta or 1 medium potato on training days
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Progressive resistance training (PRT) with lean red meat
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control PRT
Number of subjects: 152
Study: 23866774

Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine (ASAQ) fixed-dose combination (FDC)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 300
Study: 21924404

Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR) therapy, average of 4.1 sessions
Number of subjects: 19

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 19
Study: 18563311

Group type: EXPERIMENTAL
Intervention: nebivolol (5 mg/day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: atenolol (50 mg/day)
Number of subjects: 32
Study: 16317550

Group type: EXPERIMENTAL
Intervention: Primary sphincter-cutting procedures (fistulotomy and fistulectomy)
Number of subjects: 405

Group type: COMPARATOR
Intervention: Drainage alone
Number of subjects: 405
Study: 12142198

Group type: EXPERIMENTAL
Intervention: Zipper technique
Number of subjects: 300

Group type: COMPARATOR
Intervention: Intracutaneous suture technique
Number of subjects: 300
Study: 10211538

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 100 and 500 microg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide 300 and 500 microg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral prednisone 10 mg every morning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flunisolide 500 microg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide 500 microg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8687088

Group type: EXPERIMENTAL
Intervention: AO/ASIF implants
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Biodegradable self‐reinforced polyglycolide or polylactide devices
Number of subjects: 69

Group type: COMPARATOR
Intervention: Non‐operative treatment
Number of subjects: 69
Study: 2087015

Group type: COMPARATOR
Intervention: AS‐4370 2.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AS‐4370 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AS‐4370 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 517369

Group type: EXPERIMENTAL
Intervention: WH question format
Number of subjects: 151

Group type: COMPARATOR
Intervention: Incomplete statement format
Number of subjects: 151
Study: 6819596

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (150-300 mg per day)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Chlorimipramine (150-300 mg per day)
Number of subjects: 98